Department of Hyperbaric Medicine Athens Naval Hospital, Greece.
School of Health Sciences, Department of Nursing National and Kapodistrian University of Athens, Greece.
Undersea Hyperb Med. 2020 Fourth Quarter;47(4):561-569. doi: 10.22462/10.12.2020.5.
The treatment of avascular necrosis of the femoral head (AVNFH) is based on invasive (e.g., core decompression) and non-invasive methods (e.g., hyperbaric oxygen therapy - HBO2). The purpose of the present study is to evaluate the effect of HBO2 on the quality of life (QoL) of patients with AVNFH.
This was a prospective observational non-controlled study of patients with AVNFH treated by HBO2. It was conducted, with the use of Steinberg scale, on 73 patients with AVNFH Stage I or II who were treated with HBO2. Patients' QoL was assessed with EuroQol-5D-5L (EQ), Harris Hip Score (mHHS), MAHORN (MHOT), and VAS, in three different phases: before HBO2; after the completion of the first phase (20 HBO2 sessions, up to two months); and after the completion of the second phase (20 HBO2 sessions, up to two months after the first phase). A reassessment was made on the completion of each phase. Ratings were also made after the completion of each phase, over the first five months of follow-up.
All 73 patients (67.1% males, 32.9% females, mean age: 40.34, SD ±± 9.99) participated in the study. Steinberg scale, mean EQ (F (1, 57) = 25.18, η2 = .306 and F (1, 43) = 43.402, η2 = .502); mHHS (F (1, 61) = 67.13, η2 = .524) and F (1, 43) = 31.84, η2 = .425); MHOT (F (1, 61) = 11.68, η2 = .161) and F (1, 43) = 98.01, η2 = .695); and VAS (F (1, 53) = 24.11, η2 = .313) and F (1, 39) = 45.61, η2 = .539), improved between the first and second measurements and between the second and third measurement accordingly (p < .01).
HBO2 treatment does not induce alteration of quality of life and is well tolerated and accepted by patients.
股骨头缺血性坏死（AVNFH）的治疗基于有创（例如，核心减压）和非侵入性方法（例如，高压氧治疗 - HBO2）。本研究的目的是评估 HBO2 对 AVNFH 患者生活质量（QoL）的影响。
这是一项对接受 HBO2 治疗的 AVNFH 患者进行的前瞻性观察性非对照研究。使用 Steinberg 量表对 73 例 AVNFH I 期或 II 期患者进行了研究，这些患者接受了 HBO2 治疗。通过 EuroQol-5D-5L（EQ）、Harris 髋关节评分（mHHS）、MAHORN（MHOT）和 VAS 评估患者的 QoL，在三个不同阶段进行：接受 HBO2 治疗之前；第一阶段完成后（20 次 HBO2 治疗，持续两个月）；第二阶段完成后（第一阶段后两个月完成 20 次 HBO2 治疗）。在每个阶段完成后进行重新评估。在每个阶段完成后并在接下来的五个月随访期间进行评估。
所有 73 名患者（67.1%男性，32.9%女性，平均年龄：40.34，SD ±± 9.99）均参与了研究。Steinberg 量表、平均 EQ（F（1，57）= 25.18，η2 =.306 和 F（1，43）= 43.402，η2 =.502）；mHHS（F（1，61）= 67.13，η2 =.524）和 F（1，43）= 31.84，η2 =.425）；MHOT（F（1，61）= 11.68，η2 =.161）和 F（1，43）= 98.01，η2 =.695）；和 VAS（F（1，53）= 24.11，η2 =.313）和 F（1，39）= 45.61，η2 =.539），在第一和第二测量之间以及第二和第三测量之间相应地提高（p <.01）。
HBO2 治疗不会引起生活质量的改变，并且患者能够很好地耐受和接受。
